Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Zacks Investment Research

15 Jul 2026, 13:51 UTC · 1h ago

Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims

3 claims · each scored for market impact

What matters in this story

1
Summit Therapeutics (SMMT) has agreed to divest its investigational antibiotic candidate, ridinilazole, to Biossil Inc. — The deal provides an immediate upfront payment and potential future milestones, reducing the financial burden of a failed primary endpoint in Phase III.
+0.20
2
Summit will receive an upfront payment of $500,000 and is eligible for up to $104.5 million in future regulatory and commercial milestone payments. — While the upfront payment is small, the significant potential milestones provide a non-dilutive value capture for a project the company would otherwise abandon.
+0.15
3
Summit decided to divest ridinilazole because the FDA indicated it would likely require at least one additional Phase III study for approval. — Confirms that the asset failed its initial primary endpoints and would have required significant time and capital to reach market independently.
-0.10

Which stocks this story touches

6 related stories

Summit to Divest Late-Sta… — SMMT +0.30 | NewsImpactScreener